Page 101 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Cripto-1 in cancer diagnosis and therapy

doi: 10.56434/j.arch.esp.urol.20247701.3 stem cells. J Cell Biochem. 2022;123(7):1183-1196.
63. Tesar EC, Mikolasevic I, Skocilic I, et al. Prostate cancer doi: 10.1002/jcb.30272
scoring index for risk of progression of radioresistant 68. Annamaria S, Fabio S, Jwala PS, et al. Recombinant
disease. J Pers Med. 2023;13(5):870.
humanized Fab fragments targeting the CFC domain
doi:10.3390/jpm13050870 of human cripto-1. Biochem Biophys Res Commun.
2023;694:149417.
64. Gudbergsson JM, Duroux M. An evaluation of different
cripto-1 antibodies and their variable results. J Cell Biochem. doi: 10.1016/j.bbrc.2023.149417
2020;121(1):545-556.
69. Iaccarino E, Calvanese L, Untiveros G, et al. Structure-
doi: 10.1002/jcb.29293 based design of small bicyclic peptide inhibitors of cripto-1
activity. Biochem J. 2020;477(8):1391-1407.
65. Ligtenberg MA, Witt K, Galvez-Cancino F, et al. Cripto-1
vaccination elicits protective immunity against metastatic doi: 10.1042/Bcj20190953
melanoma. Oncoimmunology. 2016;5(5):e1128613.
70. Wang Y, Li X, Wang S, et al. miR-3929 inhibits proliferation
doi: 10.1080/2162402X.2015.1128613 and promotes apoptosis by downregulating cripto-1
expression in cervical cancer cells. Cytogenet Genome Res.
66. Ishii H, Zahra MH, Takayanagi A, Seno M. A novel
artificially humanized anti-cripto-1 antibody suppressing 2021;161:425-436.
cancer cell growth. Int J Mol Sci. 2021;22(4):1709. doi: 10.1159/000518521
doi: 10.3390/ijms22041709 71. Zang TL. Effect of combination of radiotherapy and
docetaxel on Cripto-1, b-catenin and DBC1 expression in
67. Afify SM, Hassan G, Nawara HM, et al. Optimization of
production and characterization of a recombinant soluble breast cancer patients. Indian J Exp Biol. 2024;62(1):71-76.
human Cripto-1 protein inhibiting self-renewal of cancer doi: 10.56042/ijeb.v62i01.7444

Volume 3 Issue 3 (2025) 93 doi: 10.36922/ARNM025130015